Cerebrolysin

Cerebrolysin is indicated for the treatment of cerebrovascular disorders, including acute ischemic stroke, vascular dementia, senile dementia of Alzheimer's type, and craniocerebral trauma such as commotio and contusio cerebri.¹ In acute stroke, clinical trials demonstrate early and sustained functional recovery, improvement in motor functions as measured by scales like NIHSS, mRS, and ARAT, preservation of cognitive functions, and reduced mortality in severe cases, with benefits observed as early as day 2 and persisting to day 90.² It supports neurorecovery by stimulating brain self-repair mechanisms and has shown efficacy as a standalone therapy or adjunct to recanalization and rehabilitation, enhancing sensorimotor network plasticity and independence.²,³ Studies also indicate potential cognitive improvements in dementia, though evidence for acute stroke benefits remains mixed in some reviews.⁴,⁵

Cerebrolysin's most frequently reported adverse reactions are dizziness, headache, sweating, nausea, vertigo, agitation, and feeling hot, which are generally mild, transient, and similar in incidence to placebo.⁶,⁷ Less common effects may include tremors, mild fever, local injection site reactions such as swelling, pain, or warmth (especially if injected too quickly), agitation, insomnia, gastrointestinal disturbances like vomiting or diarrhea, and rare hypersensitivity reactions including rash, dyspnea, or shock-like states.¹,⁸,⁹ Key safety considerations include contraindications in cases of hypersensitivity to its components, epilepsy or status epilepticus, and severe renal impairment; caution is advised in patients with allergic diathesis or seizure disorders due to potential increased frequency of attacks.¹,⁹,¹⁰,¹¹ It shows no significant interactions with standard therapies like tPA, statins, or cholinesterase inhibitors, but additive effects with antidepressants or MAO inhibitors may occur, necessitating dosage adjustments.¹,⁷,⁹,¹¹ Use during pregnancy or lactation should be avoided due to limited human data, despite no teratogenic effects in animals, and patients should be monitored for vital signs and lab parameters, which typically remain stable.¹,⁹,¹⁰ Driving or operating machinery is not recommended until individual tolerance is confirmed.⁹

Cerebrolysin, composed of low-molecular-weight peptides and amino acids derived from porcine brain, crosses the blood-brain barrier due to its small molecular size, enabling direct interaction with neuronal and vascular tissues in the neurovascular unit.¹²,¹³,¹⁴ It exerts multimodal effects by modifying key signaling pathways, including the sonic hedgehog (Shh) pathway to promote neurogenesis, oligodendrogenesis, and expression of miR-17-92 cluster, as well as neurotrophic factor (NTF) pathways where it mimics activities of BDNF, NGF, and CNTF, stimulates their production, and activates PI3K/Akt signaling for cell survival and plasticity.¹²,¹³,¹⁴,¹⁵ Physiologically, it provides neuroprotection against ischemic cascades by inhibiting calpain-mediated apoptosis, reducing excitotoxicity and glutamate levels, and preventing neuronal necrosis.¹⁴,¹⁶,¹⁷ Additionally, Cerebrolysin reduces endothelial inflammation by decreasing pro-inflammatory cytokine release, restoring blood-brain barrier integrity through increased tight junctions, and supporting neuroplasticity via axonal sprouting, synaptogenesis, and angiogenesis.¹²,¹⁴